NAT10 and metabolic syndrome: Although HALP has emerged in the literature as a new prognostic biomarker for poor immune response in immunodeficiency conditions, the levels of HALP score and its clinical utility have not been examined in conditions associated with chronic inflammation that create overactive inflammatory responses such as dyslipidemia, hypertension, and obesity.